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We conducted a large-scale genetic analysis on giant cell arteritis (GCA), a polygenic immune-mediated vasculitis. A case-control
cohort, comprising 1,651 case subjects with GCA and 15,306 unrelated control subjects from six different countries of European
ancestry, was genotyped by the Immunochip array. We also imputed HLA data with a previously validated imputation method to
perform a more comprehensive analysis of this genomic region. The strongest association signals were observed in the HLA region,
with rs477515 representing the highest peak (p ¼ 4.05 3 1040, OR ¼ 1.73). A multivariate model including class II amino acids of
HLA-DRb1 and HLA-DQa1 and one class I amino acid of HLA-B explained most of the HLA association with GCA, consistent with
previously reported associations of classical HLA alleles like HLA-DRB1*04. An omnibus test on polymorphic amino acid positions
highlighted DRb1 13 (p ¼ 4.08 3 1043) and HLA-DQa1 47 (p ¼ 4.02 3 1046), 56, and 76 (both p ¼ 1.84 3 1045) as relevant
positions for disease susceptibility. Outside the HLA region, the most significant loci included PTPN22 (rs2476601, p ¼ 1.73 3
106, OR ¼ 1.38), LRRC32 (rs10160518, p ¼ 4.39 3 106, OR ¼ 1.20), and REL (rs115674477, p ¼ 1.10 3 105, OR ¼ 1.63). Our study
provides evidence of a strong contribution of HLA class I and II molecules to susceptibility to GCA. In the non-HLA region, we
confirmed a key role for the functional PTPN22 rs2476601 variant and proposed other putative risk loci for GCA involved in Th1,
Th17, and Treg cell function.Introduction
Giant cell arteritis (GCA [MIM 187360]) is a chronic and
polygenic immune-mediated disease of unknown etiology
that is the most common form of vasculitis in individuals
over the age of 50 in Western countries.1,2 It is character-
ized by inflammatory damage of large- and medium-sized
arteries, particularly the extracranial branches of the ca-
rotid artery, which can lead to severe complications such
as blindness or cerebrovascular events.3,4
During the last decade, genetic association studies have
described several genes that are associated with predisposi-
tion to GCA, including genes of immune/inflammatory
pathways and genes of the human leukocyte antigen
(HLA) class I and II regions. The HLA-DRB1*04 alleles
seem to be the most consistently associated genetic risk
factors for this form of vasculitis.5
One of the most successful platforms to identify im-
mune-related risk variants is the Human Immuno DNA
Analysis BeadChip Kit (known as the Immunochip), a
custom Illumina Infinium High-Density array developed
by the Immunochip Consortium for immunogenetics
gene mapping. The Immunochip allows a dense analysis
of 196,524 SNPs, rare variants, and insertion/deletion
(indel) polymorphisms, located within 186 known sus-
ceptibility loci for autoimmune and inflammatory disor-
ders.6 The use of the Immunochip has substantially
increased the number of established genetic risk fac-
tors for multiple immune-mediated diseases, including
Takayasu arteritis (another large-vessel vasculitis [MIM
207600]),7 celiac disease (MIM 212750),8 rheumatoid
arthritis (RA [MIM 180300]),9 autoimmune thyroid disease
(MIM 275000 and 140300),10 psoriasis (MIM 177900),11
primary biliary cirrhosis (MIM 109720),12,13 juvenile idio-
pathic arthritis (MIM 604302),14 primary sclerosing chol-
angitis (MIM 613806),15 narcolepsy (MIM 161400),16
ankylosing spondylitis (MIM 106300),17 atopic derma-
titis (MIM 603165),18 and systemic sclerosis (SSc [MIM
181750]).19 The use of the same platform in all the above
studies has facilitated the identification of common aetio-
pathogenic pathways among those disorders.20
Considering the above, we decided to carry out a large-
scale genetic analysis of GCA in a well-sized case-control566 The American Journal of Human Genetics 96, 565–580, April 2, 2cohort with the Immunochip genotyping platform. Addi-
tionally, taking advantage of the high coverage that this
array has in the HLA region, we performed a comprehen-
sive analysis of the HLA region by using a novel imputa-
tion method to obtain imputed types of SNPs, classical
HLA alleles, and polymorphic amino acid positions.21,22Subjects and Methods
Study Population
Six independent case-control sample collections of European
ancestry, from Spain (763 GCA-affected individuals and 1,517 un-
affected controls), UK (251 GCA-affected individuals and 8,612
unaffected controls), North America (USA and Canada; 205
GCA-affected individuals and 1,641 unaffected controls), Italy
(238 GCA-affected individuals and 1,270 unaffected controls),
Norway (99 GCA-affected individuals and 374 unaffected con-
trols), and Germany (95 GCA-affected individuals and 1,892
unaffected controls), were included in this study. The procedures
followed were in accordance with the ethical standards of the
responsible committee on human experimentation (institutional
and national) of all participant centers, and written informed con-
sent was obtained from all individuals. All cases fulfilled the 1990
American College of Rheumatology classification criteria for
GCA,23 and the diagnosis was additionally confirmed by either a
biopsy of the temporal artery (95.35%) or arterial imaging
(4.65%). The most relevant clinical phenotypes of the case cohort
are shown in Table S1.Genotyping
Genomic DNA was extracted from blood samples by standard
methods. The genotypingwas performed on the Illumina iScan sys-
temwith the Immunochip platform, as per Illumina protocols. Two
different centers were involved in the genotyping. The sample sets
from Spain, Italy, Norway, andGermanywere genotyped by theGe-
nomics and Genotyping Unit of the Pfizer-University of Granada-
Junta de Andalucı´a Centre for Genomics and Oncological Research
(GENYO, Granada, Spain) and those from UK and North America
were genotypedby theCentre forMusculoskeletal Research (Univer-
sity of Manchester, Manchester, UK). Because of that, we used the
samegenotypingandcallingprocedures tocontrol forpossiblebatch
effects as follows: (1) genotype calling was performed with the Gen-
otyping Module (v.1.8.4) of the GenomeStudio Data Analysis soft-
ware using the NCBI build 36 (hg18) mapping (Illumina manifest
file Immuno_BeadChip_11419691_B.bpm); (2) low-quality SNPs015
of every batch were removed if they had call rates < 0.98 or cluster
separation < 0.4; and (3) the strand orientation of every batch was
set accordingly with the TOP orientation of Illumina to avoid A/T
and G/Cmismatches during the merging of the sets.Quality Control
Different quality filters were applied to the Immunochip raw
data from each cohort independently prior to the statistical ana-
lyses by PLINK v.1.07.24 SNPs with a genotyping call rate lower
than 98% and those that were not in Hardy-Weinberg equilib-
rium (HWE; p < 0.001) were removed from the analysis. Simi-
larly, subjects were excluded if fewer than 90% of SNPs were
called. In addition, principal-component (PC) analyses were per-
formed to identify and exclude outliers based on their ethnicity
by PLINK and the gcta64 and R-base under GNU Public license
v.2. With this software, we calculated and plotted the three first
PCs using the ‘‘null’’ SNPs of the Immunochip (i.e., not associ-
ated with autoimmune diseases) for each subject, and those
who deviated more than 4 SDs from the cluster centroids were
considered outliers. PC analysis was also used to confirm that
all subjects in our filtered study cohorts overlapped with the
CEU cohort of the HapMap project (Figure S1). Furthermore,
one subject per duplicate pair and per pair of first-degree relatives
was also removed via the Genome function with a Pi-HAT
threshold 0.5 in PLINK. A total of 1,651 GCA case subjects and
15,306 unrelated control subjects remained after applying the
above filters. The final genotyping call rate in the pooled dataset,
which contained information of 95,416 non-imputed genetic
variants, was 99.94%.HLA Imputation
We subsequently isolated the genotyping data from the extended
major histocompatibility complex (xMHC) region, located in
chromosome 6,25 and used a previously validated imputation
method to analyze the variation within the xMHC region of
SNPs, classical HLA alleles, and amino acidic variants.21,22 In brief,
to impute this genomic region, we used the SNP2HLA method
with the Beagle software package22,26 and a reference panel
comprised of 5,225 individuals of European origin27 with geno-
typing data of 8,961 common SNPs and indel polymorphisms
across the xMHC region, and four digits genotyping data of the
HLA class I and II molecules.28 Imputed data were also filtered
with PLINK with the following thresholds: 95% success call rate
for alleles and amino acids, deviation from HWE considering a p
value of 0.001 for SNPs in controls, and 95% total call rate for in-
dividuals. Information from a total of 7,179 SNPs, 423 classical
HLA alleles (126 at two-digit and 297 at four-digit resolution) of
HLA-A (MIM 142800), HLA-B (MIM 142830), HLA-C (MIM
142840), HLA-DRB1 (MIM 142857), HLA-DQB1 (MIM 604305),
HLA-DQA1 (MIM 146880), HLA-DPB1 (MIM 142858), and HLA-
DPA1 (MIM 142880), and 1,275 amino acidic variants were
included in the clean dataset (Table S2).HLA Imputation Accuracy
To check the imputation accuracy, we obtained sequence-based
types from a subset of 200 case subjects with GCA and unaffected
control subjects (selected randomly from the Spanish cohort
included in this study) for the classical HLA class II alleles
DQA1, DQB1, and DRB1 at four-digit resolution, using the kits
LABType SSO Class II DQA1/DQB1 Typing Test and LABType
SSO Class II DRB1 Typing Test from One Lambda, because theseThe Ammolecules harbored the most significant amino acid associations
(see below). In addition, we also used available data in our labora-
tory from 185 previously genotyped unaffected control subjects
for the class I molecule HLA-B. We then compared the genotypes
obtained serologically with the imputed ones as previously
described.21Imputation of Non-HLA Regions
We performed SNP genotype imputation of the most associated
loci outside the HLA region. For that, we isolated the genotyping
data of 5 Mb regions centered in the lead SNPs and obtained
imputed genotypes with the software IMPUTE v.2.29 The 1000 Ge-
nomes Phase 3 was used as reference panel.30 The probability
threshold for merging genotypes was established at 0.9. Imputed
data were subsequently subjected to stringent quality filters in
PLINK, i.e., individuals who generated genotypes at <90% were
removed from the datasets, and SNPs with call rates <98% and
those that deviated from HWE in control subjects (p < 0.001)
were also discarded.Statistical Analyses
CaTS Power Calculator for Genetic Studies, which implements the
methods described in Skol et al.,31 was used to estimate the statis-
tical power of our study (Table S3).
The statistical analyses were performed with PLINK and R. To
test for association, we compared the variation frequencies of
case and control subject by logistic regression on the best-guess
genotypes (>0.9 probability) assuming an additive model with
the three first PCs, the gender, and the country of origin as co-
variates. A minimal difference in the results was observed after
adjusting for five or ten PCs. Inverse variance weighted fixed ef-
fects meta-analysis was also used to evaluate the consistency of
the results of the non-HLA region. For the HLA region, we tested
SNPs, classical HLA alleles, and all possible combinations of
amino acid residues per position. Statistical significance was es-
tablished by comparison of the deviance model to the null
model as previously described.19,22 Cochran’s Q and I2 tests
were used to measure the heterogeneity of the ORs across
studies.
The omnibus association test was also performed to determine
the influence of the polymorphic amino acid positions in the
disease susceptibility, as described.21 We established a null gener-
alized linear model, which included the first three PCs, the
country of origin, and gender as variables. Then, an alternative
model was built for each position, including the previously
described variables and all the possible alleles in the analyzed
positions. Finally, both models were compared with a likelihood
ratio test. This gives rise to a n  1 degrees of freedom test,
where n is the number of alternative alleles at that position.
Additionally, we also conducted conditional analyses controlling
the amino acid positions by the most associated positions with a
putative functional effect in our set (conditioning factors). In
these conditional analyses, the conditioning factors were
included in both the null and the alternative models. By these
means, we could test the association of all residues in the
analyzed positions but including the conditioning factors as co-
variates in the models.
The haplotypes of the associated amino acid positions were also
evaluated by additive logistic regression. Amino acid combina-
tions with a frequency < 1% in control groups were excluded
from this analysis.erican Journal of Human Genetics 96, 565–580, April 2, 2015 567
Figure 1. Manhattan Plot Representation of the Immunochip Results
The log10 of the combined logistic regression test p values are plotted against their physical chromosomal position. The red line rep-
resents the genome-wide level of significance (p< 53 108), and the blue line represents the statistical significance for suggestive signals
(p < 1 3 104). The most relevant associations are highlighted.To identify independent effects, dependency analyses by step-
wise logistic regression were carried out with conditioning by
the most associated signals, as described.9 The statistical signifi-
cance was set at 5 3 108. Odds ratios (OR) and 95% confidence
intervals (CI) were also calculated. The Manhattan plots were
obtained with an in-house modification of the R script written
by Stephen Turner, and the 3D models of the HLA molecules
were performed with the UCSF Chimera software.32 The online
tool of LocusZoom v.1.133 was used to plot the results of the
imputed regions.Analysis of Enrichment of Rheumatoid-Arthritis-
Associated Variants
Considering that previous candidate gene studies5 and the re-
sults reported here (see below) suggested a possible overlap be-
tween part of the genetic background of RA and GCA, we carried
out an analysis of enrichment of confirmed RA-associated alleles
in our GCA cohort. With this aim, we calculated in PLINK a ge-
netic score predicting RA risk for each participant in our study by
obtaining a weighted mean of genotype dosage across 52 RA-
associated variants. These include the 5 amino acids conferring
higher risk in the amino acid model proposed by Raychaudhuri
et al.21 and 47 non-HLA SNPs (22 exact ones and 25 proxies with
r2 > 0.9 in the CEU population of the 1000 Genomes project)
out of the 101 reported in Okada et al.34 The remaining SNPs
were not used to calculate the scores either because they were
not included in our GCA dataset or because they had a
reduced statistical significance in the European population
(p < 1 3 106).
The effect estimates used to weight the scores were the log of the
ORs reported for the European population in Table S1 of Okada
et al.34 and the per-allele ORs (i.e., assuming an additive genetic
model) reported in the Table S4 of Raychaudhuri et al.21 Table S4
summarizes the main aspects of the variants included in the
analysis.
To analyze the possible difference between the score distribu-
tion in case and control subjects, a null generalized linear model
including the first three PCs, country of origin, and gender as vari-
ables was compared against an alternative model including the568 The American Journal of Human Genetics 96, 565–580, April 2, 2same variables and the RA risk scores by the means of a likelihood
ratio test in R.Results
Association signals at the genome-wide level of signifi-
cance were observed only in the combined analysis
(Figure 1) and in the independent analyses of the cohorts
with higher statistical power, i.e., Spain, UK, and North
America (Figure S2). In all cases, those signals were located
within the HLA region at chromosome 6 (Table S5).
Deep Interrogation of the HLA Region
To narrow down the HLA association with GCA, we
inferred SNPs, classical HLA alleles, and polymorphic
amino acid positions. The overall accuracy reached after
comparing four-digit types with the corresponding
imputed data was 99.48% for HLA-DQA1, 98.45% for
HLA-DQB1, 89.94% for HLA-DRB1, and 88.11% for HLA-
B (Table S6 and Figure S3).
After the imputation, high association peaks were
observed in HLA-DRB1*04, HLA-DQA1*03, and HLA-
DQB1*03 alleles (Table 1), particularly HLA-DRB1*04:04
(p ¼ 2.12 3 1023, OR ¼ 2.28), HLA-DQA1*03:01 (p ¼
1.38 3 1035, OR ¼ 1.85), and HLA-DQB1*03:02 (p ¼
3.93 3 1028, OR ¼ 1.90). Consequently, different amino
acids included in those alleles were also strongly associated
with disease predisposition in the combined analysis
(Table S5). However, the peak signal corresponded to a
SNP (rs477515, p ¼ 4.05 3 1040, OR ¼ 1.73) in high link-
age disequilibrium (LD; r2 ¼ 0.43, D’ ¼ 1.00) with a group
of SNPs and amino acids of HLA-DRB1 in complete LD
with one another that have a stronger effect size (OR ¼
1.92), including a His in position 13 (p ¼ 5.12 3 1038,
OR ¼ 1.92) located in the binding groove of the mole-
cule.35 This SNP maps to the intergenic region between015
Table 1. Genome-wide Significant Associations of Classical HLA Alleles with Giant Cell Arteritis without Conditioning at Two- and Four-
Digit Resolution
Classical
HLA Allele
Allele Frequency
Meta-analysisSpain UK North America Italy Norway Germany
GCA CTRL GCA CTRL GCA CTRL GCA CTRL GCA CTRL GCA CTRL p Value OR (95% CI)
DRB1*04 0.2104 0.1276 0.3247 0.1944 0.2854 0.1651 0.1155 0.0736 0.3182 0.2233 0.2263 0.1453 6.78 3 1038 1.92 (1.74–2.12)
DQA1*03 0.2156 0.1381 0.3327 0.2069 0.3024 0.1758 0.1218 0.0776 0.3384 0.2326 0.2368 0.1564 1.38 3 1035 1.85 (1.68–2.04)
DQA1*01 0.3014 0.3767 0.2410 0.3885 0.2732 0.4007 0.2668 0.3622 0.2727 0.4412 0.3211 0.4382 3.84 3 1029 0.61 (0.56–0.67)
DQB1*03 0.3847 0.3174 0.4781 0.3434 0.4415 0.3501 0.4475 0.4193 0.4697 0.3262 0.4316 0.3380 5.15 3 1019 1.44 (1.33–1.56)
DQB1*05 0.1560 0.1823 0.0737 0.1550 0.0878 0.1697 0.1471 0.2291 0.0657 0.1578 0.1053 0.1662 2.94 3 1015 0.63 (0.56–0.71)
DQB1*06 0.1455 0.1941 0.1693 0.2339 0.1854 0.2310 0.1197 0.1331 0.2071 0.2834 0.2053 0.2717 4.28 3 1010 0.72 (0.65–0.80)
DRB1*14 0.0125 0.0290 0.0159 0.0247 0.0171 0.0286 0.0189 0.0654 0.0051 0.0227 0.0053 0.0217 7.23 3 109 0.40 (0.29–0.54)
DQA1*0301 0.2156 0.1381 0.3327 0.2069 0.3024 0.1758 0.1218 0.0776 0.3384 0.2326 0.2368 0.1564 1.38 3 1035 1.85 (1.68–2.04)
DQB1*0302 0.1481 0.0962 0.1773 0.1047 0.2098 0.0984 0.0924 0.0547 0.2778 0.1444 0.1526 0.1084 3.93 3 1028 1.90 (1.69–2.12)
DRB1*0404 0.0826 0.0369 0.0877 0.0485 0.0829 0.0372 0.0231 0.0098 0.1313 0.0588 0.0579 0.0299 2.12 3 1023 2.28 (1.94–2.68)
DRB1*0401 0.0695 0.0340 0.2012 0.1154 0.1415 0.0865 0.0420 0.0193 0.1667 0.1417 0.1263 0.0959 2.77 3 1018 1.80 (1.58–2.06)
DQA1*0101 0.1415 0.1575 0.0677 0.1458 0.0805 0.1493 0.1050 0.1768 0.0556 0.1524 0.0947 0.1451 8.83 3 1013 0.64 (0.57–0.73)
DQA1*0102 0.1035 0.1368 0.1295 0.1889 0.1415 0.1856 0.0840 0.1315 0.1566 0.2126 0.1421 0.2106 2.02 3 1010 0.68 (0.61–0.77)
DQB1*0503 0.0125 0.0284 0.0159 0.0255 0.0171 0.0283 0.0210 0.0634 0.0051 0.0214 0.0053 0.0211 3.21 3 108 0.42 (0.31–0.57)HLA-DRB1 and HLA-DQA1 genes and has no putative reg-
ulatory effect according to the regulomeDB database
(score ¼ 6), although a possible relevant function of
rs477515 can not be ruled out.
Dependence Analysis
We then hypothesized that the HLA association with GCA
might be explained by polymorphic amino acid residues,
as reported for other immune-mediated diseases,21,36,37
and we carried out further logistic regression analysis of
the HLA data controlling for the most associated amino
acid residues. If the most associated signals were in high
LD, we selected for those located in the binding pocket
of their corresponding molecule.
A summary of the logistic regression analysis is shown
in Figure 2. First, we included the above-mentioned
HLA-DRb1 His13 amino acid as covariate, which
decreased considerably the statistical significance of the
class-II-associated signals (highest peak: rs3104407, p ¼
3.27 3 1016, OR ¼ 0.70; Figure 2B). Subsequently, the
addition to the model of a glycine (Gly) in position 56
of the HLA-DQa1 chain explained the association at the
genome-wide level of significance observed in the class
II region, although some independent signals in class I
(i.e., amino acids in positions 45 and 97 of HLA-B and
the SNP rs3130944) still remained (highest peak: presence
of Arg or Thr in position 97 of HLA-B, p ¼ 1.36 3 108;
Figure 2C). Finally, when a Thr in position 45 of the
HLA-B molecule was included in the condition list, all
the class I variants were non-significant (Figure 2D).
Hence, the model that best explained the HLA associationThe Amwith GCA included HLA-DRb1 His13 (p ¼ 5.12 3 1038,
OR ¼ 1.92), HLA-DQa1 Gly56 (p ¼ 3.84 3 1029, OR ¼
0.61), and HLA-B Thr45 (p ¼ 3.78 3 109, OR ¼ 0.76)
(Table S5). However, it should be noted that we based
our analysis on the hypothesis that the leading drivers
are most likely to be located in antigen-binding pockets
of the HLA molecules and, therefore, other putative
models (e.g., including the rs477515 genetic variant)
might also explain our data equally well.
Omnibus Test
We also tested the possible influence of the polymorphic
amino acid positions by means of an omnibus test (Table
S7 and Figure S4). The most associated signals corre-
sponded to the HLA-DQa1 positions 47, 56, and 76
(p ¼ 4.02 3 1046, p ¼ 1.84 3 1045, and p ¼ 1.84 3
1045, respectively). Regarding the latter, DQa1 76 might
harbor three amino acid residues (Val76, Met76, and
Leu76) that are in complete LD with the three possible
variants in DQa1 56 (Arg56, Gly56, and *56) and, there-
fore, they cannot be distinguished by statistical analysis
alone. In relation to DQa1 47, four amino acids can be
present at this position (Gln47, Arg47, Lys47, and
Cys47). Two of them (Gln47 and Arg47) are in complete
LD with amino acids of DQa1 56-76 and form two haplo-
types, i.e., Gln47-Arg56-Val76 (haplotype A, conferring
risk) and Arg47-Gly56-Met76 (haplotype B, conferring
protection) (Figure 3A, Table S8). The third and fourth
possible DQa1 47 amino acids also form two other
haplotypes with DQa1 *56-Leu (haplotype C, Lys47-*56-
Leu76; and haplotype D, Cys47-*56-Leu76), but thoseerican Journal of Human Genetics 96, 565–580, April 2, 2015 569
Figure 2. Manhattan Plot Representa-
tion of the Step-wise Conditional Logistic
Regression of the HLA Region
(A) Unconditioned test of the HLA region.
(B) Results of the HLA region after condi-
tioning to HLA-DRb1 His13.
(C) Results of the HLA region after condi-
tioning to HLA-DRb1 His13 and HLA-
DQa1 Gly56.
(D) Results of the HLA region after condi-
tioning to HLA-DRb1 His13, HLA-DQa1
Gly56, and HLA-B Thr45.
Thelog10 of the combined logistic regres-
sion test p values are plotted against their
physical chromosomal position. A red/
blue color gradient was used to represent
the effect size of each analyzed variant
(red for risk and blue for protection). The
red line represents the genome-wide level
of significance (p < 5 3 108).haplotypes did not reach statistical significance (Table
S8). Position 13 of HLA-DRb1 also showed high associa-
tion (p ¼ 4.08 3 1043), and the only class-I-associated
position was HLA-B 45 (p ¼ 4.12 3 109). It was not
possible to unambiguously established casualty from
HLA-DRb1 13 over DQa1 positions 47, 56, and 76 due
to the high LD between some of the amino acids at those
positions (Table S8).
Considering the similarity in the association with RA
susceptibility observed for the positions 11 and 13 of
HLA-DRb1,21 we conditioned these two positions one
to another to analyze possible casualty in GCA. Contrary
to that observed in RA, position 11 completely lost its
statistical significance after conditioning on position 13
(conditioned p ¼ 0.64), whereas a suggestive p value was570 The American Journal of Human Genetics 96, 565–580, April 2, 2015observed for position 13 after condi-
tioning on position 11 (conditioned
p ¼ 6.74 3 106).
Table 2 summarizes the results of
the associated amino acids within
the positions comprising our pro-
posed model to explain the HLA asso-
ciation with GCA.
Additionally, similar to that
observed in the analysis of the spe-
cific amino acid residues, no statisti-
cally significant signals were detected
after including the amino acids of
HLA-DRb1 13, HLA-DQa1 56, and
HLA-B 45 as conditioning factors in
the analyses (Figure S4).
Haplotype Analysis
Taking into account the high LD of
the class II HLA genomic region,
we decided to carry out a haplotype
test combining all the possible
amino acids present in the class IIpositions of the model (Figure 3). Although different
haplotypes surpassed the genome-wide significance
threshold, none of them showed a significant improve-
ment in the association observed for the associated
amino acids of HLA-DRb1 13 and DQa1 47, 56, and 76
independently. Similar results were observed when
the haplotypes were examined including the amino
acids of position 45 of the class I molecule HLA-B
(Table S9). This was consistent with the fact that: (1)
HLA-DRb1 His13 and the haplotype A of HLA-DQa1
(Gln47-Arg56-Val76), which are in high LD (r2 ¼ 0.92),
defined the higher association signal in the haplotype
analysis (p ¼ 4.12 3 1037, OR ¼ 1.90); (2) all the
most significant risk haplotypes included the amino
acid HLA-DRb1 His13 (DRb1 His13 - DQa1 haplotype
Table 2. HLA Residues Associated at the Genome-wide Level of Significance of the Amino Acid Positions Included in the Model that Best
Explains the HLA Association with Giant Cell Arteritis
Molecule
Amino Acid
Residues Population
Residue Frequency
p Value OR (95% CI) Classical HLA AllelesGCA CTRL
HLA-DRb1 His13* Meta-analysis 5.12 3 1038 1.92 (1.74–2.12) 04:01, 04:02, 04:03, 04:04,
04:05, 04:07, and 04:08
Spain 0.2097 0.1272 7.24 3 1014 1.94 (1.63–2.31)
UK 0.3247 0.1944 1.81 3 1012 2.00 (1.65–2.43)
North America 0.2854 0.1651 9.44 3 109 2.02 (1.59–2.57)
Italy 0.1155 0.0724 1.54 3 103 1.71 (1.23–2.37)
Norway 0.3182 0.2233 9.29 3 103 1.64 (1.13–2.38)
Germany 0.2263 0.1451 2.19 3 103 1.77 (1.23–2.54)
Ser13* Meta-analysis 3.27 3 108 0.79 (0.73–0.86) 03:01, 11:01, 11:02, 11:03,
11:04, 13:01, 13:02, 13:03,
13:05, 14:01, and 14:02Spain 0.3270 0.4123 9.70 3 10
9 0.68 (0.60–0.78)
UK 0.1633 0.2087 1.57 3 102 0.74 (0.58–0.95)
North America 0.3317 0.3699 1.53 3 101 0.85 (0.68–1.06)
Italy 0.4958 0.5028 8.88 3 101 0.99 (0.81–1.20)
Norway 0.3030 0.3115 8.00 3 101 0.95 (0.67–1.37)
Germany 0.3737 0.3739 8.36 3 101 0.97 (0.71–1.32)
HLA-DQa1 Gln47 Meta-analysis 1.38 3 1035 1.85 (1.68–2.04) 03:01
Arg56* Spain 0.2156 0.1381 4.86 3 1012 1.81 (1.53–2.15)
Val76 UK 0.3327 0.2069 3.36 3 1011 1.91 (1.58–2.31)
North America 0.3024 0.1758 4.32 3 109 2.02 (1.60–2.56)
Italy 0.1218 0.0776 1.52 3 103 1.69 (1.22–2.34)
Norway 0.3384 0.2326 4.20 3 103 1.71 (1.19–2.47)
Germany 0.2368 0.1564 3.26 3 103 1.71 (1.20–2.44)
Arg47 Meta-analysis 3.84 3 1029 0.61 (0.56–0.67) 01:01, 01:02, and 01:03
Gly56* Spain 0.3014 0.3767 2.20 3 107 0.70 (0.61–0.80)
Met76 UK 0.2410 0.3885 5.27 3 1011 0.50 (0.41–0.61)
North America 0.2732 0.4007 1.46 3 106 0.56 (0.44–0.71)
Italy 0.2668 0.3622 5.40 3 105 0.64 (0.52–0.79)
Norway 0.2727 0.4412 3.68 3 105 0.46 (0.32–0.67)
Germany 0.3211 0.4382 1.90 3 103 0.60 (0.44–0.83)
HLA-B Thr45* Meta-analysis 3.78 3 109 0.76 (0.69–0.83) 18:01, 35:01, 35:02, 35:03,
35:08, 35:12, 37:01, 51:01,
51:06, 51:08, 52:01, 53:01,
and 58:01
Spain 0.2608 0.3082 5.57 3 104 0.78 (0.68–0.90)
UK 0.1175 0.1703 1.80 3 103 0.65 (0.49–0.85)
North America 0.1756 0.2383 6.83 3 103 0.69 (0.53–0.90)
Italy 0.3718 0.4331 1.87 3 102 0.78 (0.64–0.96)
Norway 0.1162 0.1551 1.48 3 101 0.70 (0.43–1.13)
Germany 0.2105 0.2167 8.83 3 101 0.97 (0.68–1.39)
The classical HLA alleles in our dataset that contain those amino acids are shown. Asterisk (*) indicates amino acids involved in antigen binding.A, p ¼ 4.12 3 1037, OR ¼ 1.90; DRb1 His13 - DQa1
haplotype A - B Glu45, p ¼ 9.09 3 1020, OR ¼ 2.52;
DRb1 His13 - DQa1 haplotype A - B Met45, p ¼ 1.03 3
1018, OR ¼ 2.78; DRb1 His13 - DQa1 haplotype A - B
Lys45, p ¼ 3.05 3 1014, OR ¼ 1.86); and (3) haplotypeThe AmB of DQa1 (Arg47-Gly56-Met76) was included in the
haplotypes conferring higher protection (DRb1 Ser13 -
DQa1 haplotype B, p ¼ 7.72 3 1016, OR ¼ 0.52; DRb1
Ser13 - DQa1 haplotype B - B Thr45, p ¼ 9.16 3 108,
OR ¼ 0.39).erican Journal of Human Genetics 96, 565–580, April 2, 2015 571
Figure 3. Haplotypes Observed in Our
Dataset between the Residues of the Class
II Positions of the Model that Best Ex-
plains the Association of This Genomic Re-
gion with Giant Cell Arteritis
(A) Graphical representation of the four
haplotypes formed by the amino acids of
the DQa1 positions 47, 56, and 76. The fre-
quency of every amino acid is shown in
brackets.
(B) Each row refers to the haplotype of one
HLA-DRb1 13 amino acid and one HLA-
DQa1 haplotype. Haplotype frequencies
of case subjects (red) and control subjects
(blue), odds ratios (OR), and log10 of the
logistic regression test p values are plotted.
A red/blue color gradient was used in the
OR bars to represent the effect size of
each analyzed variant (red for risk and
blue for protection).Analysis of the Non-HLA Region
No associations at the genome-wide significance level were
detected when the non-HLA region was analyzed by logis-
tic regression (Table 3). Two genetic variants of the protein
tyrosine phosphatase non-receptor type 22 (PTPN22 [MIM
600716]) gene in almost complete LD (r2 ¼ 0.99) repre-
sented the highest non-HLA association signal with GCA
(rs6679677, p ¼ 1.31 3 106, OR ¼ 1.39; rs2476601, p ¼
1.73 3 106, OR ¼ 1.38). One of them (rs2476601) is a
non-synonymous (p.Arg620Trp) functional variant that
has been associated with a variety of immune-mediated
diseases,38 including GCA (in a study with partial
overlap of the sample collections with this one).39 Sugges-
tive association (p < 104) was also found for another two
tightly linked SNPs (r2 ¼ 0.99) located in the leucine-rich
repeat containing 32 (LRRC32 [MIM 137207]) region
(rs10160518, p ¼ 4.39 3 106, OR ¼ 1.20; rs2155219,
p ¼ 6.19 3 106, OR ¼ 1.19). Other suggestive signals
included SNPs of key immune-related genes such as v-rel
avian reticuloendotheliosis viral oncogene homolog (REL
[MIM 164910]; rs115674477, p ¼ 1.10 3 105, OR ¼
1.63), protein kinase C theta (PRKCQ [MIM 600448];
rs587198, p ¼ 5.72 3 105, OR ¼ 1.17), cluster domain
226 (CD226 [MIM 605397]; rs1788110, p ¼ 6.51 3 105,
OR ¼ 0.85), and NLR family pyrin domain containing
6 (NLRP6 [MIM 609650]; rs3817637, p ¼ 8.67 3 105,
OR ¼ 0.77).
Similar results were observed when the dataset was
analyzed with inverse variance weighted meta-analysis
(Table S10). However, in this analysis REL rs115674477
corresponded with the second top signal, with a statistical
significance (p ¼ 3.56 3 106, OR ¼ 1.67) very similar to
that observed for PTPN22.572 The American Journal of Human Genetics 96, 565–580, April 2, 2015In order to conduct a more
detailed analysis of the top signals,
we obtained imputed data of the
PTPN22, LRRC32, and REL genomic
regions. A total of 922 SNPs inthe PTPN22 region, 462 in the LRRC32 region, and
1,158 in the REL region were included in the imputed
datasets. However, because of the dense coverage of
the fine-mapped loci in the Immunochip, all the
imputed variants showed a lower statistical significance
than PTPN22 rs2476601, LRRC32 rs10160518, and
REL rs115674477 (Figure 4), consistent with previous
studies.19
We checked the statistical significance of genes reported
to be associated with GCA in candidate gene studies.5
Although the signals were relatively weak, associations at
p < 0.05 were observed in most cases (Table S11 and
Figure S5), e.g., nitric oxide synthase 2 inducible (NOS2
[MIM 163730]; rs2274894, p ¼ 1.58 3 103, OR ¼ 1.14),
interleukin 6 (IL6 [MIM 147620]; rs10242595, p ¼ 3.70 3
103, OR ¼ 0.89), IL4 ([MIM 147780]; rs2243200, p ¼
4.47 3 103, OR ¼ 6.86), interferon gamma (IFNG [MIM
147570]; rs2193046, p ¼ 5.08 3 103, OR ¼ 0.89), and
IL10 ([MIM 124092]; rs74148796, p ¼ 7.84 3 103, OR ¼
0.83).
Considering that a shared genetic component might in-
fluence the development of different autoimmune pheno-
types,20,40 we also checked the results of specific known
susceptibility SNPs for immune-mediated diseases in our
dataset accordingly with the reported data in Table S5 of Ri-
can˜o-Ponce and Wijmenga.40 Associations at the nominal
level (p < 0.05) between GCA and several autoimmune
SNPs were observed (Table S12), with PTPN22 rs6679677/
rs2476601 (associated with RA, type 1 diabetes [MIM
222100], and Crohn disease [MIM 266600], among others)
and LRRC32 rs10160518/rs2155219 (associated with ulcer-
ative colitis, UC [MIM 266600]) representing the strongest
signals.
Table 3. Signals outside the HLA Region Showing a Trend of Association of p < 104 with Giant Cell Arteritis
Chr rs ID
Position
Locus
Minor/
Major
Allele
Minor Allele Frequency
Meta-analysisSpain UK North America Italy Norway Germany
(GRCh36) GCA CTRL GCA CTRL GCA CTRL GCA CTRL GCA CTRL GCA CTRL p Value OR (95% CI)
1 rs6679677 114105331 PTPN22 A/C 0.097 0.063 0.112 0.095 0.129 0.097 0.050 0.035 0.136 0.115 0.121 0.112 1.31 3 106 1.39
(1.22–1.58)
1 rs2476601 114179091 PTPN22 A/G 0.098 0.064 0.112 0.095 0.129 0.098 0.050 0.036 0.131 0.115 0.121 0.111 1.73 3 106 1.38
(1.21–1.58)
11 rs10160518 75974319 LRRC32 A/G 0.500 0.447 0.528 0.494 0.522 0.490 0.494 0.465 0.561 0.529 0.605 0.513 4.39 3 106 1.20
(1.11–1.29)
11 rs2155219 75976842 LRRC32 C/A 0.499 0.446 0.528 0.494 0.520 0.490 0.494 0.465 0.561 0.531 0.605 0.514 6.19 3 106 1.19
(1.11–1.29)
2 rs115674477 60965427 REL G/A 0.039 0.029 0.032 0.023 0.039 0.016 0.034 0.017 0.046 0.036 0.032 0.019 1.10 3 105 1.63
(1.31–2.03)
21 rs2236430 32895279 TCP10L-
C21orf59
A/G 0.306 0.293 0.347 0.317 0.349 0.320 0.387 0.302 0.389 0.297 0.437 0.361 1.33 3 105 1.20
(1.11–1.30)
11 rs2508740 75904830 C11orf30 G/A 0.375 0.425 0.383 0.396 0.359 0.395 0.366 0.399 0.364 0.436 0.321 0.388 2.06 3 105 0.84
(0.78–0.91)
11 rs1892952 76042374 LRRC32 A/G 0.528 0.473 0.496 0.480 0.524 0.501 0.532 0.495 0.525 0.480 0.558 0.491 4.11 3 105 1.17
(1.09–1.27)
6 rs11752919 28511582 ZSCAN23 G/A 0.347 0.407 0.363 0.409 0.363 0.359 0.263 0.280 0.313 0.365 0.332 0.339 5.22 3 105 0.84
(0.78–0.92)
11 rs7926009 75845110 C11orf30 G/A 0.388 0.435 0.388 0.407 0.381 0.410 0.382 0.412 0.374 0.448 0.342 0.398 5.51 3 105 0.85
(0.79–0.92)
11 rs10790958 127862477 ETS1 C/G 0.320 0.301 0.351 0.323 0.354 0.295 0.267 0.226 0.404 0.338 0.384 0.330 5.71 3 105 1.19
(1.09–1.29)
10 rs587198 6571155 PRKCQ G/A 0.447 0.401 0.484 0.453 0.459 0.451 0.490 0.461 0.525 0.433 0.516 0.454 5.72 3 105 1.17
(1.09–1.27)
18 rs1788110 65719816 CD226 G/C 0.321 0.337 0.257 0.318 0.334 0.337 0.334 0.411 0.298 0.369 0.295 0.320 6.51 3 105 0.85
(0.78–0.92)
10 rs10749570 90028013 C10orf59 A/C 0.277 0.343 0.309 0.335 0.327 0.344 0.319 0.324 0.301 0.366 0.358 0.360 7.27 3 105 0.84
(0.78–0.92)
14 rs10149689 80485553 C14orf145-
TSHR
G/A 0.417 0.458 0.462 0.449 0.395 0.456 0.410 0.467 0.399 0.447 0.358 0.404 7.36 3 105 0.85
(0.79–0.92)
11 rs3817637 275920 NLRP6-
ATHL1
A/G 0.091 0.124 0.084 0.114 0.122 0.115 0.090 0.134 0.152 0.128 0.090 0.121 8.67 3 105 0.77
(0.68–0.88)
11 rs10160382 75804862 PRKRIR-
C11orf30
G/A 0.321 0.357 0.331 0.354 0.322 0.351 0.332 0.363 0.328 0.385 0.284 0.343 9.60 3 105 0.85
(0.78–0.92)
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Figure 4. Regional Plots of the Three Most Associated Loci with GCA outside the HLA Region in the Overall Meta-analysis after
Imputation
(A) Protein tyrosine phosphatase non-receptor type 22 (PTPN22) region.
(B) v-rel avian reticuloendotheliosis viral oncogene homolog (REL) region.
(C) Leucine-rich repeat containing 32 (LRRC32) region.
(D) Results for the LRRC32 region after conditioning for the lead SNP (rs10160518).
Red arrows point to the lead variants (highlighted in violet).Polygenic Risk Score Analysis
Taking into account that some of the most associated var-
iants with GCA are confirmed RA risk factors, we calculated
polygenic risk scores predictive for RA susceptibility in our
samples and tested whether there were differences in the
distribution of the scores between case and control sub-
jects (Figure 5). Three different scores were constructed
per sample: (1) with all the RA-associated variants, (2)
including only the non-HLA SNPs, and (3) considering
only the HLA amino acids conferring higher susceptibility
to RA.21 In the three analyses, themean score was higher in
the GCA set that in control subjects. The most significant
differences between case and control subjects were
observed when the scores were calculated with all the
RA variants (likelihood p value ¼ 9.32 3 1028; Figures
5A and 5B). The difference of the score distribution be-
tween case and control subjects was also highly significant
when only the five RA-risk amino acids were considered to
calculate the scores (likelihood p value¼ 3.713 1023; Fig-
ures 5E and 5F). Although a less significant p value was ob-574 The American Journal of Human Genetics 96, 565–580, April 2, 2tained with the scores calculated with the non-HLA alleles,
there was still some evidence of an effect (likelihood
p value ¼ 5.573 106; Figures 5C and 5D). However, these
results must be interpreted with caution, because they sug-
gest only that RA and GCA case subjects are genetically
more similar to each other than each is to healthy control
subjects. Further analyses are needed to obtain a better esti-
mation of the shared genetic component between this
type of vasculitis and other immune-mediated diseases.Discussion
This study was performed with a large GCA cohort of indi-
viduals from different European ancestries that cover the
whole gradient in prevalence for populations of European
descent.41
Our data show strong evidence for substantial involve-
ment of HLA class II region in the pathophysiology of
GCA. We confirmed the previous associations of GCA015
Figure 5. Distributions of Genetic Risk
Score Predictive for Susceptibility to
Develop Rheumatoid Arthritis by Disease
Status
(A, C, and E) Histogram of genetic risk
scores calculated with all the RA alleles
(A), with non-HLA alleles only (C), or
with HLA alleles only (E).
(B, D, and F) Distribution curve of genetic
risk scores calculated with all the RA alleles
(B), with non-HLA alleles only (D), or with
HLA alleles only (F).with HLA-DRB1*04 alleles (both 04:01 and 04:04).42–49 We
also identified HLA-DQA1 as an independent novel suscep-
tibility factor for GCA, specifically the classical alleles
DQA1*0101, DQA1*0102, and HLA-DQA1*03:01. The
level of statistical significance observed within the HLA re-
gion in our study highlights the importance of the im-
mune system in the development of GCA. Our results are
consistent with the hypothesis of dysregulated interac-
tions between the vessel wall and immune cells as respon-
sible for the development of large-vessel vasculitides.50
Novel imputation methods are allowing the identifica-
tion of specific amino acid positions of HLA molecules
associated with immune-mediated diseases, including
RA,21,51 SSc,19 and Behc¸et disease (BD [MIM 109650]),36
thus increasing our understanding of the complex HLA as-
sociations with different autoimmune processes. With this
state-of-the-art methodology, we built a model including
class II amino acid positions (HLA-DRb1 13 and HLA-
DQa1 47, 56, 76) and one class I amino acid position
(HLA-B 45) that explained most of the HLA association
with GCA in our study cohort. Some of these amino acid
positions are located in the binding groove of their corre-
sponding HLA molecules and are directly involved in the
peptide binding35,52–54 (Figure 6).
According to our results, the presence of a Thr in posi-
tion 45 of HLA-B might be protective of the development
of GCA. Interestingly, classical HLA alleles containing
Thr45, such as HLA-B*51:01, have been associated with
a delay in the onset of AIDS (MIM 609423)-defining dis-
eases and a better control of HIV infection.55 In addition,The American Journal of HumanHLA-B*51 (particularly 51:01) has
been identified as the strongest
known genetic risk factor for BD,
another type of vasculitis, although
HLA-B 45 does not seem to be a rele-
vant position for this association.36
However, no significant risk effects
were observed for any of the other
amino acids (Met, Glu, and Lys) of
this position in our sample set,
despite the strong influence that this
position seems to have on the fea-
tures of the bound peptides.54 This
could be the reason for the lower sta-
tistical significance of this position inthe omnibus test compared with the associated positions
of HLA-DQa1 and HLA-DRb1. Both class II molecules har-
bor amino acids with strong effect sizes in both sides (e.g.,
risk for HLA-DRb1 His13 / HLA-DQa1 haplotype A, and
protection for HLA-DRb1 Ser13 / HLA-DQa1 haplotype B).
In relation to HLA-DQa1, Arg56 is directly involved in
hydrogen bonding to the DQ2.5-glia-g-4c epitope,52 and
it might represent a critical position in the binding groove
of the HLA-DQ molecule. Additionally, DQA1*01 alleles
containing HLA-DQa1 Gly56 have been recently associ-
ated with immune-mediated disorders. For example, a
model including DQA1*01:02 (together with DRB1*03:01
and DRB1*08:01) has been proposed to explain the HLA
associations with systemic lupus erythematosus (MIM
152700).56 Similarly, homozygosity of DQA1*01:02 seems
to play a crucial role in the development of narcolepsy
with cataplexy.57
In contrast to the data on DQ*, HLA-DRb1 His13 is
included in the previously identified GCA-associated
alleles HLA-DRB1*04:01 and HLA-DRB1*04:04.42–49 This
amino acid is in tight LD with the top most associated po-
sition with RA (HLA-DRb1 Val11).21 In the study of RA, it
was not possible to unambiguously assign causality to
one position at the exclusion of the other, indicating
that HLA-DRb1 His13 cannot be ruled out as the major
contributor to the HLA association with RA.21 Indeed,
the two more associated amino acids with RA and GCA
risk at those positions (HLA-DRb1 His13 and HLA-DRb1
Val11) showed also a high LD in our dataset (r2 ¼ 0.94),
and it could be possible that HLA-DRb1 11 represents aGenetics 96, 565–580, April 2, 2015 575
Figure 6. Ribbon Representation of the HLAMolecules HLA-DR,
HLA-DQ, and HLA-B/b2 Microglobulin
The amino acid positions of the HLA model associated with GCA
are highlighted in orange.causal position for GCA. However, the effect sizes observed
for both the HLA-DRb1 Val11 residue (p ¼ 2.22 3 1032,
OR ¼ 1.80) and the HLA-DRb1 11 position (p ¼ 5.06 3
1037) were clearly lower than those observed for HLA-
DRb1 His13 (5.12 3 1038, OR ¼ 1.92) and position 13
of HLA-DRb1 (p ¼ 4.08 3 1043) in our study. In addition,
the effect of position 11 in GCA susceptibility was com-
pletely eliminated after conditioning on position 13
(p ¼ 0.64), whereas a suggestive association with position
13 remained after conditioning on position 11 (p ¼
6.74 3 106).
Remarkably, candidate gene studies in GCA suggested
that this vasculitis shares some of its genetic component
with RA.5 Our data clearly support this hypothesis, because
two out of the three top signals outside the HLA region in
our Immunochip study, PTPN22 and REL, are important
susceptibility factors for RA.34,58,59 In addition, PRKCQ,
another RA risk gene of the REL pathway,60 is also among
the most significant loci in our study. The above is consis-
tent with the clear difference that we observed in the poly-
genic risk scores predictive for RA risk between GCA case
and control subjects.
Furthermore, theautoimmunedisease-associatedPTPN22
SNP rs2476601/p.Arg620Trp, which is a central negative
regulator of both B and T cell receptor signaling,61 was
the top signal in the non-HLAanalysis ofGCA. There is con-
troversy about the suitability of using the strict genome-
wide significance threshold (5 3 108) in Immunochip
studies,62 because the design of this custom array was not
based on SNPs tagging the whole genome but on the fine-
mapping of immune genes.6 We estimated that the total
number of independent signals in our filtered dataset was
23,791 (indep-pairwise option of PLINK with values 50 5
0.2) and, therefore, an appropriate Bonferroni-based statisti-
cal threshold for our study could be considered 2.103 106.
Similarly, with the Genetic type 1 Error Calculator (GEC)
software, which implements a previously validatedmethod
to calculate the threshold for statistical significance required576 The American Journal of Human Genetics 96, 565–580, April 2, 2to control the genome-wide type 1 error rate at 0.05,63
1.77 3 106 was obtained as significance threshold for our
study. Hence, with this criterion, PTPN22 rs2476601 would
represent a confirmed associated variant in GCA. This same
genetic variant was recently identified by our group as a sus-
ceptibility factor for this type of vasculitis through a candi-
date gene strategy, via using a GCA sample collection that
partially overlaps (48%) with the one analyzed here.39
Therefore, this study confirms PTPN22 as the non-HLA
gene with greatest effect susceptibility to GCA described to
date, as it occurs in RA.64
Regarding REL, it should be noted that rs115674477 ap-
pears as an isolated singleton in our study. Considering its
low frequency (MAF < 0.03), reasonable doubts might
arise about the reliability of this association. However,
the consistency of the effect sizes observed for this SNP
across the different populations suggests that it might
represent a real association signal. REL encodes a member
of the NF-kB family of transcription factors known as
c-Rel, which is involved in T cell and antigen-presenting
cell function.65 It has been demonstrated that c-Rel regu-
lates the expression of the Th1-cell-promoting cytokine
IL-12 and the Th17-cell-promoting cytokine IL-23 in den-
dritic cells and macrophages, respectively.66,67 Further-
more, c-Rel is also required for the expression of FoxP3, a
master regulator in the development and function of reg-
ulatory T (Treg) cells.68,69 Interestingly, the second non-
HLA hit in our study, LRRC32 (also known as glycoprotein
A repetition predominant protein [GARP]), is highly ex-
pressed in activated Treg cells and it could also control
the expression of FoxP3.70,71 It has been reported that
the surface localization of LRRC32 alters the surface
expression of T cell activation markers and that LRRC32þ
Treg cells mediate more suppressive signals than
LRRC32 Treg cells.72 Genetic variants of LRRC32 have
been associated through genome-wide association studies
with UC, atopic dermatitis, and allergic rhinitis (MIM
607154).73–75 In UC and allergic rhinitis, the associated
variant corresponded with rs215521,73,75 one of the two
linked LRRC32 SNPs that are more significantly associated
with GCA in our study. Considering that current knowl-
edge points to Th1, Th17, and Treg cells, together with
dendritic cells and macrophages, as the most relevant
cell types in GCA pathophysiology,76,77 we propose
that both LRRC32 and REL might represent true risk fac-
tors for this type of vasculitis, albeit not reaching the
genome-wide level of significance.
In summary, through a comprehensive screening of
immune loci, we have derived a testable model of
different HLA amino acid positions (HLA-DRb1 13,
HLA-DQa1 47, 56, 76, and HLA-B 45) that explains
most of the HLA association with GCA. However, it is
important to note that, despite the clear biological impli-
cation of our model, there was insufficient statistical po-
wer in the current dataset to definitively confirm these
positions as the true causal drivers of the HLA association
with GCA, considering the high level of LD within this015
genomic region. Consequently, it should be tested in
future studies.
Additionally, our data implicate other putative suscepti-
bility genes outside the HLA region, such as PTPN22,
LRRC32, and REL, which encode key proteins involved in
T cell function. Further collaborative efforts are necessary
to increase the sample size of the current GCA cohorts
and to definitively confirm these loci at the genome-wide
level of significance. Replication of our findings in inde-
pendent GCA cohorts with greater statistical power and
functional studies confirming the involvement of the pro-
posed variants in the disease pathophysiology would also
be desirable to substantiate them.Supplemental Data
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